海外の治験の状況「前立腺癌」での検索結果
25件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Phase II Trial of MK-3475 in Subjects with mCRPC
- Metastatic Castration-Resistant Prostate Cancer (mCRPC) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, Estonia, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
- 2016-04-15
Authorised
- Phase II Trial of MK-3475 in Subjects with mCRPC with Prior Chemotherapy
- Metastatic Castration-Resistant Prostate Cancer (mCRPC) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, Estonia, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
- 2016-04-15
Authorised
- MULTICENTRE, SINGLE-ARM, OPEN LABEL CLINICAL TRIAL INTENDED TO PROVIDE EARLY ACCESS TO CABAZITAXEL IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER PREVIOUSLY TREATED WITH A DOCETAXEL-CONTAINING REGIMEN AND TO DOCUMENT SAFETY OF CABAZITAXEL IN THESE PATIENTS
- Metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen MedDRA version: 14.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Canada, China, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Malaysia, Mexico, Philippines, Portugal, Singapore, Spain, Sweden, Taiwan, United Kingdom
- 2010-10-08
Authorised
- An International Study to Evaluate the effectiveness of continuing treatment of enzalutamide after PSA Progression in Patients who have not yet received chemotherapy.
- Patients With Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer. br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Denmark, Finland, France, Germany, Italy, Slovakia, Spain, Sweden, United Kingdom, United States
- 2013-10-14
Authorised
- An International Study to Evaluate the effectiveness of continuing treatment of enzalutamide after PSA Progression in Patients who have not yet received chemotherapy.
- Patients With Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer. br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Denmark, Finland, France, Germany, Italy, Slovakia, Spain, Sweden, United Kingdom, United States
- 2013-09-10
